Cowen reiterates Unilever stock rating on growth outlook

Unilever reported Q4 2025 revenue of $12.59B, missing consensus $15.95B by ~21%, a material shortfall that likely pressured the stock. TD Cowen reiterated a Buy with a GBP58.00 price target citing strong fundamentals (P/E 21.6, PEG 0.32, Piotroski score 9) and expects 2% volume growth in 2026, while Berenberg downgraded to Hold but raised its PT to GBP58.40. The company’s strategic shift, recent acquisitions (Liquid I.V., Nutrafol, Dr. Squatch, Minimalist), and management changes are cited as long-term positives despite the near-term earnings miss.

Analysis

Unilever’s ongoing shift to a category-led, P&L-driven model creates a two-speed risk profile: near-term volatility as the company trims low-margin portfolios and integrates bolt-on brands, versus multi-year upside if market share and SKU rationalization drive consistent gross-margin expansion. Expect margin tailwinds to lag sales stabilization by 6–12 months because SCM and marketing efficiencies take quarters to realize and because smaller acquired brands often require incremental upfront marketing spend that masks early margin gains.

Competitively, the clearest beneficiary of any investor skepticism will be legacy U.S. household champions and niche premium personal-care players that can demonstrate faster organic velocity per marketing dollar; they will see relative multiple re-rating if investors mark Unilever down for execution risk. Conversely, ingredient suppliers and co-packers exposed to concentrated personal-care SKUs should see order resilience if the category momentum proves real, creating positive earnings leverage for those mid-cap industrial names.

Key catalysts to watch: rolling 3-quarter organic volume trends, incremental margin contribution from recent acquisitions, and analyst revisions to long-run growth assumptions. Tail risks that would flip the thesis include protracted float of integration costs, renewed commodity inflation that compresses gross margins, or FX-driven translation hits — any of which could knock valuation convergence off its timeline and amplify downside over 3–12 months.

Key Decisions for Investors

• Pair trade (6–12 months): long PG (size to target +8–12% absolute) vs short UL (size to target -15–20%). Rationale: capture re-rating of U.S. household peer if market penalizes UL for near-term execution; stop-loss if spread narrows by 6% or if UL reports two consecutive quarters of margin improvement.
• Tactical hedge (3–6 months): buy UL 3–6 month put spread (bear put) sized <3% portfolio to capture downside from execution/earnings risk. Risk/reward: max loss = premium (~100%), target 20–30% downside in UL equity, close on confirmatory negative revision or at 50% of realized premium.
• Conviction long (12–36 months): accumulate UL via out-of-the-money Jan 2028 call spreads (bull call) on pullbacks to realize multi-year re-rating if volume gains persist. Risk/reward: limited downside (premium), asymmetric upside 2x–4x if market restores multiple; trim at first signs of sustainable margin beat.
• Supply-chain play (6–18 months): overweight mid-cap personal-care co-packers and ingredient suppliers (select names) with visible exposure to concentrated SKUs, underweight ice-cream/low-margin food suppliers. Rationale: capture order rotation and higher incremental margins; target 15–25% upside if category portability proves durable.